Form 4: Alan Mateo, 10x Genomics Director, Reports Acquisition of 21,691 Shares of Class A Common Stock

Director Alan Mateo reports acquiring 21,691 shares of 10x Genomics Class A Common Stock on July 31, 2024, through restricted stock units.

Summary

• Alan Mateo, a director of 10x Genomics, Inc. (TXG), filed a Form 4 on August 2, 2024, reporting a transaction that occurred on July 31, 2024.
• The transaction involved the acquisition of 21,691 shares of Class A Common Stock.
• These shares were acquired through restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• 1/3rd of the RSUs shall vest on August 21, 2025 and 1/12th of the RSUs shall vest on each quarterly anniversary thereafter for the following two years, subject to the Reporting Person continuing as a service provider through each such date.
• Following the reported transaction, Mateo beneficially owns 21,691 shares of Class A Common Stock directly.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document is a standard SEC filing reporting a director's acquisition of shares through RSUs. It doesn't inherently convey positive or negative sentiment, but insider buying is often viewed as a mildly positive signal.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting schedule of the RSUs extends over two years, contingent on the reporting person's continued service.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of company stock, which is a common occurrence.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates